|
US9266891B2
(en)
|
2012-11-16 |
2016-02-23 |
Boehringer Ingelheim International Gmbh |
Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors
|
|
US9073878B2
(en)
|
2012-11-21 |
2015-07-07 |
Zenith Epigenetics Corp. |
Cyclic amines as bromodomain inhibitors
|
|
US9765039B2
(en)
|
2012-11-21 |
2017-09-19 |
Zenith Epigenetics Ltd. |
Biaryl derivatives as bromodomain inhibitors
|
|
CN105073744B
(zh)
|
2012-12-21 |
2019-11-08 |
齐尼思表观遗传学有限公司 |
作为溴结构域抑制剂的新型杂环化合物
|
|
BR112015022942B1
(pt)
|
2013-03-15 |
2022-02-22 |
Incyte Holdings Corporation |
Compostos heterocíciclos tricíclicos, método para inibir proteína bet in vitro e composição farmacêutica compreendendo os referidos compostos
|
|
EA027139B1
(ru)
|
2013-04-26 |
2017-06-30 |
Бейджин, Лтд. |
Замещенные 5-(3,5-диметилизоксазол-4-ил)индолин-2-оны
|
|
SG10201710705UA
(en)
|
2013-06-21 |
2018-02-27 |
Zenith Epigenetics Ltd |
Novel bicyclic bromodomain inhibitors
|
|
WO2015004533A2
(en)
|
2013-06-21 |
2015-01-15 |
Zenith Epigenetics Corp. |
Novel substituted bicyclic compounds as bromodomain inhibitors
|
|
ES2635560T3
(es)
|
2013-07-08 |
2017-10-04 |
Incyte Holdings Corporation |
Heterociclos tricíclicos como inhibidores de la proteína NET
|
|
EP3027604B1
(en)
|
2013-07-31 |
2019-02-20 |
Zenith Epigenetics Ltd. |
Novel quinazolinones as bromodomain inhibitors
|
|
US9315501B2
(en)
|
2013-11-26 |
2016-04-19 |
Incyte Corporation |
Bicyclic heterocycles as BET protein inhibitors
|
|
US9399640B2
(en)
|
2013-11-26 |
2016-07-26 |
Incyte Corporation |
Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
|
|
WO2015095492A1
(en)
|
2013-12-19 |
2015-06-25 |
Incyte Corporation |
Tricyclic heterocycles as bet protein inhibitors
|
|
NZ725930A
(en)
|
2014-04-23 |
2023-04-28 |
Incyte Holdings Corp |
1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins
|
|
US9902702B2
(en)
*
|
2014-07-15 |
2018-02-27 |
Bristol-Myers Squibb Company |
Spirocycloheptanes as inhibitors of rock
|
|
ES2855225T3
(es)
|
2014-09-15 |
2021-09-23 |
Incyte Corp |
Heterociclos tricíclicos para su uso como inhibidores de proteínas BET
|
|
CN107429246B
(zh)
|
2014-10-31 |
2021-06-01 |
麻省理工学院 |
用于crispr的大规模并行组合遗传学
|
|
HK1246273B
(en)
|
2014-12-01 |
2019-12-06 |
恒翼生物医药(上海)股份有限公司 |
Substituted pyridines as bromodomain inhibitors
|
|
HK1245246A1
(zh)
|
2014-12-01 |
2018-08-24 |
恒翼生物医药科技(上海)有限公司 |
作为溴域抑制剂的取代吡啶酮
|
|
JP2017537946A
(ja)
|
2014-12-11 |
2017-12-21 |
ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． |
ブロモドメイン阻害剤としての置換複素環
|
|
CA2966450A1
(en)
|
2014-12-17 |
2016-06-23 |
Olesya KHARENKO |
Inhibitors of bromodomains
|
|
JP2018527293A
(ja)
*
|
2015-06-16 |
2018-09-20 |
オリオン コーポレーション |
ブロモドメイン阻害剤としてのスピロ［シクロブタン−１，３’−インドリン］−２’−オン誘導体
|
|
WO2016203335A1
(en)
|
2015-06-18 |
2016-12-22 |
Pfizer Inc. |
Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
|
|
AR106520A1
(es)
|
2015-10-29 |
2018-01-24 |
Incyte Corp |
Forma sólida amorfa de un inhibidor de proteína bet
|
|
EP3472157B1
(en)
|
2016-06-20 |
2023-04-12 |
Incyte Corporation |
Crystalline solid forms of a bet inhibitor
|
|
WO2018109271A1
(en)
*
|
2016-12-13 |
2018-06-21 |
Orion Corporation |
New bromodomain inhibitors
|
|
CN107739370B
(zh)
*
|
2017-10-26 |
2021-03-30 |
中国药科大学 |
吡咯酮类brd4蛋白抑制剂的制备方法以及用途
|
|
CN109928979B
(zh)
*
|
2017-12-15 |
2021-08-06 |
四川科伦博泰生物医药股份有限公司 |
吲哚酮类衍生物及其制备方法和用途
|
|
CN108383771A
(zh)
*
|
2018-01-08 |
2018-08-10 |
华东师范大学 |
手性3,3-二取代异吲哚啉-1-酮衍生物及其合成方法和应用
|
|
EP3843714B1
(en)
|
2018-08-27 |
2025-11-12 |
Arcus Biosciences, Inc. |
Cd73 inhibitors
|
|
US11396502B2
(en)
|
2018-11-13 |
2022-07-26 |
Incyte Corporation |
Substituted heterocyclic derivatives as PI3K inhibitors
|
|
WO2020102150A1
(en)
|
2018-11-13 |
2020-05-22 |
Incyte Corporation |
Heterocyclic derivatives as pi3k inhibitors
|
|
WO2020102198A1
(en)
|
2018-11-13 |
2020-05-22 |
Incyte Corporation |
Heterocyclic derivatives as pi3k inhibitors
|
|
BR112021019957A2
(pt)
|
2019-04-09 |
2021-12-07 |
Plexxikon Inc |
Azinas condensadas para modulação de ep300 ou cbp e indicações da mesma
|
|
WO2021065980A1
(ja)
|
2019-09-30 |
2021-04-08 |
協和キリン株式会社 |
Ｂｅｔ分解剤
|
|
WO2021175432A1
(en)
|
2020-03-04 |
2021-09-10 |
Boehringer Ingelheim International Gmbh |
Method for administration of an anti cancer agent
|
|
EP3912625A1
(en)
|
2020-05-20 |
2021-11-24 |
Kaerus Bioscience Limited |
Novel maxi-k potassium channel openers for the treatment of fragile x associated disorders
|
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
|
EP4580618A2
(en)
*
|
2022-08-30 |
2025-07-09 |
Pannex Therapeutics Inc. |
Pannexin-1 modulators and methods of treating disorders in which pannexin-1 is implicated
|
|
WO2025233532A1
(en)
|
2024-05-10 |
2025-11-13 |
Les Laboratoires Servier |
Maxi-k potassium channel openers and therapeutic applications thereof
|